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1638Exploring the Role of
Transcatheter Aortic
Valve Replacement as the
Preferred Treatment for
Lower-Risk PatientsThe investigators of the NOTION (Nordic Aortic Valve
Intervention) trial showed that in an all-comers pop-
ulation of patients with severe aortic stenosis, trans-
catheter aortic valve replacement (TAVR) using the
CoreValve self-expanding bioprosthesis (Medtronic
Inc., Minneapolis, Minnesota) yielded similar rates of
the composite endpoint of all-cause death, stroke, or
myocardial infarction at 1 year compared with surgi-
cal bioprosthetic aortic valve replacement (1). Their
study is the ﬁrst to assess in a randomized trial the
results of TAVR in a population including a high
proportion of patients with low surgical risk (81.8% of
patients). The scope of their ﬁndings paves the way
toward the expanded use of TAVR, from extreme- to
high-risk patients (2–5) to patients bearing lower
surgical risks. However, the results of the primary
analysis do not allow comment on the effects of TAVR
among low-risk population. As the CoreValve trial
taught (5), high-risk patients undergoing a self-
expandable TAVR yield better outcomes (lower mor-
tality) than with surgical bioprosthetic aortic valve
replacement. It is likely that, among both groups of
the NOTION trial, adverse events were concentrated
in the minority of moderate- to high-risk patients,
mirroring the results of the high-risk CoreValve trial.
Consequently, clinical equipoise, with low event rates
in both groups, is more than likely among their low-
risk patient population. Although Thyregod et al.
have to be commended for their pioneer work, this
information is currently not available in their report.
Obviously, with only 280 enrolled patients, the current
trial lacks power to identify signiﬁcant differences
among important subgroups; however, to provide the
rates of adverse events between TAVR and surgical
bioprosthetic aortic valve replacement among their
low-risk population would be highly informative,
potentially disruptive, and could help to foster future
investigations. Although ongoing trials (PARTNER
IIA [Placement of AoRTIc TraNscathetER Valves]
[NCT01314313], SURTAVI [Safety and Efﬁcacy Study of
the Medtronic Corevalve System in the Treatment of
Severe, Symptomatic Aortic Stenosis in Intermediate
Risk Subjects Who Need Aortic Valve Replacement]
[NCT01586910]) will bring more deﬁnitive answers
related to the place of TAVR in the treatment oflower-risk patients, the authors are encouraged to
provide additional analysis of the primary outcome in
patients according to their surgical risks.Guillaume Marquis Gravel, MD, MSc
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1790–8.REPLY: Exploring the Role of Transcatheter
Aortic Valve Replacement as the Preferred
Treatment for Lower-Risk PatientsIn the NOTION (Nordic Aortic Valve Intervention) trial
(1), we included all eligible patients with stand-alone
severe aortic valve stenosis. This resulted in a patient
population with a mean Society of Thoracic Surgeons
Predicted Risk of Mortality score of 3.0% and 82%
considered at low surgical mortality risk (a score lower
than 4%). The 2 other randomized trials comparing
transcatheter aortic valve replacement versus surgical
aortic valve replacement included high-risk patients
with a mean Society of Thoracic Surgeons Predicted
Risk of Mortality score of 11.7% (2) and 7.4% (3). As
noted by Drs. Gravel and Généreux, the outcomes of
our trial could potentially be driven by outcomes pri-
marily in intermediate- and high-risk patients,
constituting 18% of the sample size, and would there-
fore not reﬂect results for true low-risk patients.
However, this was not what we found as will be
demonstrated in an upcoming publication of the
NOTION trial 2-year results.
FIGURE 1 Association Between Log-Transformed Risk of All Bleeding and ST With
Noncardiovascular and Cardiovascular Mortality, Respectively
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The size of each circle represents the precision of each estimate (the inverse variance of
the log relative risk in the trial), and the line is the best ﬁt for the metaregression model.We read with interest the meta-analyses of Giustino
et al. (1) and Palmerini et al. (2) recently published in
the Journal. These studies add meaningfully to the
ongoing debate on dual antiplatelet therapy (DAPT)
duration, but their conclusions on mortality are
conﬂicting, with Giustino et al. (1) concluding that
prolonging DAPT increases all-cause mortality and
Palmerini et al. (2) demonstrating no signiﬁcant effect
on this endpoint. Indeed, addressing the net beneﬁt of
extended DAPT requires preliminary clariﬁcation of
the relative weights of stent thrombosis (ST) and
bleeding on mortality, an issue that has not been
explored by any trial or meta-analysis of DAPT dura-
tion. We hypothesized that in the contemporary era of
drug-eluting stents, ST and bleeding have a different
impact on mortality. To explore this hypothesis, we
performed a meta-regression of the effects sizes of ST
and bleeding on mortality in trials of DAPT duration,
including the recently presented I-LOVE-IT (EvaluateSafety and Effectiveness of the Tivoli DES and the
Firebird DES for Treatment of Coronary) 2 randomized
substudy (China Interventional Therapeutics, March
19, 2015, Beijing, China). Trials were excluded if
the outcomes of interest were not available. Risk ratios
for treatment effects in individual trials were
log-transformed before being used as independent
variables in linear meta-regression analyses. Statisti-
cal analyses were performed using the open-source
R Software (R Foundation for Statistical Computing,
Vienna, Austria). We found a signiﬁcant association
between all bleeding and noncardiovascular mortality
across individual studies (8 trials; intercept value [IV]:
-0.15; slope estimate [SE]: 0.61; p ¼ 0.01) (Figure 1, top
graph), while there was no evidence of a signiﬁcant
correlation of all bleeding with both cardiovascular (8
trials; IV: -0.46; SE: -0.17; p ¼ 0.69) and all-cause
mortality (10 trials; IV: -0.33; SE: 0.75; p ¼ 0.18). On
the other hand, no signiﬁcant associations were found
between ST and both cardiovascular (9 trials; IV: 0.75;
